Eagle Pharma (EGRX) Sell Off Overdone - RBC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to Eagle Pharma (EGRX) Sell Off Overdone - RBC

Eagle Pharmaceuticals Receives Complete Response Letter from FDA on KANGIO (RTU bivalirudin) Application

March 18, 2016 6:50 AM EDT

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) (Eagle or the Company) today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its KANGIO (bivalirudin injection), 505(b)(2) New Drug Application for a ready-to-use (RTU), stable liquid intravenous formulation of 5 mg/mL bivalirudin in a 50-mL vial intended for use as an anticoagulant in patients: (1) undergoing percutaneous coronary intervention (PCI) with use of glycoprotein IIb/IIIa inhibitor, (2) undergoing PCI with, or at risk of, heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), and/or (3) with unstable... More